Access

You are not currently logged in.

Access your personal account or get JSTOR access through your library or other institution:

login

Log in to your personal account or through your institution.

Capravirine, A Nonnucleoside Reverse-Transcriptase Inhibitor in Patients Infected with HIV-1: A Phase 1 Study

Benjamin E. Gewurz, Mark Jacobs, Jo Ann Proper, Thomas A. Dahl, Tamio Fujiwara and Bruce J. Dezube
The Journal of Infectious Diseases
Vol. 190, No. 11 (Dec. 1, 2004), pp. 1957-1961
Published by: Oxford University Press
Stable URL: http://www.jstor.org/stable/30077732
Page Count: 5
  • Download ($42.00)
  • Subscribe ($19.50)
  • Cite this Item
Capravirine, A Nonnucleoside Reverse-Transcriptase Inhibitor in Patients Infected with HIV-1: A Phase 1 Study
Preview not available

Abstract

Capravirine is a nonnucleoside reverse-transcriptase inhibitor (NNRTI) with a unique resistance profile. Although single mutations allow resistance to established NNRTIs, human immunodeficiency virus (HIV)-l must undergo multiple mutations to achieve resistance to capravirine. In the present phase 1 study, capravirine was administered orally for up to 28 days to 55 HIV-1-infected individuals with $CD4^+$ T lymphocyte counts of 50-500 cells/µL. The most frequent adverse events were diarrhea (5%) and nausea (4%), with no drugrelated rashes observed. The day 15 median (mean) HIV-1 load decreased by 1.34 (1.45) $log_{10}$ copies/mL in the patients receiving 25 mg/kg/day. Capravirine demonstrated potent antiviral activity, even in antiretroviral-experienced patients.

Page Thumbnails

  • Thumbnail: Page 
1957
    1957
  • Thumbnail: Page 
1958
    1958
  • Thumbnail: Page 
1959
    1959
  • Thumbnail: Page 
1960
    1960
  • Thumbnail: Page 
1961
    1961